Immatics Advances PRAME Cell Therapy and Expands Oncology Pipeline
PremiumCompany AnnouncementsImmatics Advances PRAME Cell Therapy and Expands Oncology Pipeline
3M ago
Immatics price target lowered to $13 from $15 at BofA
Premium
The Fly
Immatics price target lowered to $13 from $15 at BofA
3M ago
Immatics Faces Termination of Key Collaboration with Bristol Myers Squibb
Premium
Company Announcements
Immatics Faces Termination of Key Collaboration with Bristol Myers Squibb
4M ago
Immatics announces clinical data on TCER IMA402 targeting PRAME
PremiumThe FlyImmatics announces clinical data on TCER IMA402 targeting PRAME
5M ago
Immatics Sees Revenue Surge Despite R&D Expenses
Premium
Company Announcements
Immatics Sees Revenue Surge Despite R&D Expenses
5M ago
Immatics sees cash runway into 2H27
Premium
The Fly
Immatics sees cash runway into 2H27
5M ago
Immatics 16.25M share Spot Secondary priced at $9.25
PremiumThe FlyImmatics 16.25M share Spot Secondary priced at $9.25
6M ago
Immatics announces proposed $150M underwritten public offering
Premium
The Fly
Immatics announces proposed $150M underwritten public offering
6M ago
Immatics files automatic mixed securities shelf
Premium
The Fly
Immatics files automatic mixed securities shelf
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100